Current Therapeutic Strategies in Clinical Urology,Molecular Pharmaceutics

当前位置： X-MOL 学术 › Mol. Pharmaceutics › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Current Therapeutic Strategies in Clinical Urology
Molecular Pharmaceutics ( IF 4.5 ) Pub Date : 2018-06-20 00:00:00 , DOI: 10.1021/acs.molpharmaceut.8b00383
Alice Crane ₁ , Sudhir Isharwal ₁ , Hui Zhu ₁

Affiliation

The field of urology encompasses all benign and malignant disorders of the urinary tract and the male genital tract. Urological disorders convey a huge economic and patient quality-of-life burden. Hospital acquired urinary tract infections, in particular, are under scrutiny as a measure of hospital quality. Given the prevalence of these pathologies, there is much progress still to be made in available therapeutic options in order to minimize side effects and provide effective care. Current drug delivery mechanisms in urological malignancy and the benign urological conditions of overactive bladder (OAB), interstitial cystitis/bladder pain syndrome (IC/BPS), and urinary tract infection (UTI) will be reviewed herein. Both systemic and local therapies will be discussed including sustained release formulations, nanocarriers, hydrogels and other reservoir systems, as well as gene and immunotherapy. The primary focus of this review is on agents which have passed the preclinical stages of development.

中文翻译：

临床泌尿外科的当前治疗策略

泌尿科领域包括泌尿道和男性生殖道的所有良性和恶性疾病。泌尿科疾病带来了巨大的经济和患者生活质量负担。医院获得性泌尿道感染，尤其是医院质量的衡量标准正在接受审查。考虑到这些病理的普遍性，为了使副作用最小化并提供有效的护理，可用的治疗选择仍有许多进展。本文将对泌尿系统恶性肿瘤和膀胱过度活动症（OAB），间质性膀胱炎/膀胱疼痛综合征（IC / BPS）和尿路感染（UTI）的良性泌尿系统疾病的当前药物输送机制进行综述。将讨论全身和局部疗法，包括缓释制剂，纳米载体，水凝胶和其他储液系统，以及基因和免疫疗法。本综述的主要重点是经过临床前开发阶段的药物。

更新日期：2018-06-20

点击分享查看原文

点击收藏

阅读更多本刊最新论文本刊介绍/投稿指南11